Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK. Mardiana S, et al. Among authors: henderson ma. Cancer Res. 2017 Mar 15;77(6):1296-1309. doi: 10.1158/0008-5472.CAN-16-1831. Epub 2017 Jan 12. Cancer Res. 2017. PMID: 28082401
Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.
Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK. Beavis PA, et al. Among authors: henderson ma. Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17. Cancer Immunol Res. 2018. PMID: 30018045
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, Scolyer RA, Long GV, Wilmott JS, Loi S, Darcy PK, Beavis PA. House IG, et al. Among authors: henderson ma. Clin Cancer Res. 2020 Jan 15;26(2):487-504. doi: 10.1158/1078-0432.CCR-19-1868. Epub 2019 Oct 21. Clin Cancer Res. 2020. PMID: 31636098
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.
Lai J, Mardiana S, House IG, Sek K, Henderson MA, Giuffrida L, Chen AXY, Todd KL, Petley EV, Chan JD, Carrington EM, Lew AM, Solomon BJ, Trapani JA, Kedzierska K, Evrard M, Vervoort SJ, Waithman J, Darcy PK, Beavis PA. Lai J, et al. Among authors: henderson ma. Nat Immunol. 2020 Aug;21(8):914-926. doi: 10.1038/s41590-020-0676-7. Epub 2020 May 18. Nat Immunol. 2020. PMID: 32424363
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
Giuffrida L, Sek K, Henderson MA, Lai J, Chen AXY, Meyran D, Todd KL, Petley EV, Mardiana S, Mølck C, Stewart GD, Solomon BJ, Parish IA, Neeson PJ, Harrison SJ, Kats LM, House IG, Darcy PK, Beavis PA. Giuffrida L, et al. Among authors: henderson ma. Nat Commun. 2021 May 28;12(1):3236. doi: 10.1038/s41467-021-23331-5. Nat Commun. 2021. PMID: 34050151 Free PMC article.
CD73: A potential biomarker for anti-PD-1 therapy.
Beavis PA, Slaney CY, Milenkovski N, Henderson MA, Loi S, Stagg J, Kershaw MH, Darcy PK. Beavis PA, et al. Among authors: henderson ma. Oncoimmunology. 2015 May 5;4(11):e1046675. doi: 10.1080/2162402X.2015.1046675. eCollection 2015 Nov. Oncoimmunology. 2015. PMID: 26451321 Free PMC article.
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.
Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK. Beavis PA, et al. Among authors: henderson ma. J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6. J Clin Invest. 2017. PMID: 28165340 Free PMC article.
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.
Dushyanthen S, Teo ZL, Caramia F, Savas P, Mintoff CP, Virassamy B, Henderson MA, Luen SJ, Mansour M, Kershaw MH, Trapani JA, Neeson PJ, Salgado R, McArthur GA, Balko JM, Beavis PA, Darcy PK, Loi S. Dushyanthen S, et al. Among authors: henderson ma. Nat Commun. 2017 Sep 19;8(1):606. doi: 10.1038/s41467-017-00728-9. Nat Commun. 2017. PMID: 28928458 Free PMC article.
248 results